CRISPR Therapeutics
CRSP
CRSP
35 hedge funds and large institutions have $211M invested in CRISPR Therapeutics in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.41% less ownership
Funds ownership: 24.7% → 24.29% (-0.41%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
35
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$1.74M | |
| 2 | +$1.1M | |
| 3 | +$364K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$150K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$110K |
Top Sellers
| 1 | -$4.29M | |
| 2 | -$1.22M | |
| 3 | -$527K | |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$303K |
| 5 |
Millennium Management
New York
|
-$241K |